Johnson & Johnson's Promising Results in Oncology and Commitment to Innovation

2023-06-20

Johnson & Johnson (NYSE:JNJ) held its Goldman Sachs 44th Annual Global Healthcare Conference Call on June 13, 2023, at 4:20 PM ET. The call was attended by Biljana Naumovic, Worldwide Vice President, Oncology, and Mark Wildgust, Medical Affairs, from Johnson & Johnson, and Chris Shibutani from Goldman Sachs.

During the call, Naumovic discussed the company's progress in oncology, highlighting the success of their latest drug, which has shown promising results in clinical trials. She also discussed the company's commitment to developing innovative treatments for cancer patients and improving patient outcomes.

Wildgust provided an update on the company's medical affairs division, discussing the team's efforts to ensure the safety and efficacy of Johnson & Johnson's products. He also highlighted the company's commitment to transparency and working closely with regulatory agencies to ensure compliance with all regulations.

Shibutani asked several questions related to the company's financial performance, including their revenue growth and plans for future investments. Naumovic and Wildgust provided detailed responses, highlighting the company's strong financial position and commitment to investing in research and development.

Overall, the Johnson & Johnson team provided a comprehensive update on the company's progress in oncology and medical affairs, as well as their commitment to financial growth and responsible investment. The call demonstrated the company's dedication to improving patient outcomes and driving innovation in the healthcare industry.